President Donald Trump announced a landmark agreement with AstraZeneca that aims to significantly lower U.S. drug prices by tying them to the lowest prices offered in other developed nations. This move expands the administration’s “most-favored-nation” (MFN) policy, which seeks to ensure that Americans do not pay more for prescription drugs than patients in countries with regulated healthcare systems. The deal follows a similar arrangement made earlier with Pfizer and represents a key step in Trump’s broader effort to reduce prescription drug costs for both Medicaid recipients and direct-to-consumer purchases.
The agreement requires AstraZeneca to provide all of its medications to state Medicaid programs at the MFN price—the lowest available price for the same drug in any other developed country. The White House estimates this could save American taxpayers hundreds of millions of dollars each year. Trump emphasized that for too long, Americans have borne the burden of the world’s highest drug prices, effectively subsidizing cheaper medications abroad. The new policy targets this imbalance and is expected to benefit approximately 9 million patients currently using AstraZeneca’s products, including treatments for asthma, COPD, cardiovascular diseases, and cancer.
In addition to the pricing arrangement, AstraZeneca has pledged to invest $50 billion in U.S. pharmaceutical manufacturing and research by 2030. A major component of this investment includes the construction of a new manufacturing facility in Charlottesville, Virginia, which is expected to create around 3,600 jobs. The facility will specialize in the production of active pharmaceutical ingredients used in the company’s respiratory and oncology medications. This move is designed not only to strengthen the domestic drug supply chain but also to reduce dependence on foreign production, an issue that has gained urgency in the wake of the COVID-19 pandemic.
The White House highlighted substantial cost reductions for several key medications under the new deal. For instance, BEVESPI AEROSPHERE, used to treat COPD, will see an average price reduction of 654%, while AIRSUPRA, an asthma inhaler, will be discounted by 96% for those purchasing it directly. Consumers will also be able to access discounted drugs through a new federal online platform currently being developed by the Department of Health and Human Services. This platform will allow patients to buy medications directly from manufacturers at significantly lower prices than those found in retail pharmacies.
The agreement with AstraZeneca follows a similar MFN pricing deal with Pfizer, which was announced just ten days prior. Pfizer also committed to offering Medicaid patients lower prices and participating in the upcoming “TrumpRx” online platform. The company promised that a wide range of its products—including vaccines, blood thinners, and cancer treatments—would be available at an average 50% discount. Both deals underscore the Trump administration’s strategy to close the price gap between U.S. and international drug markets by pressuring pharmaceutical companies to align American prices with those negotiated abroad.
According to the administration, Americans pay more than three times as much for the same brand-name drugs as patients in other high-income countries, even when factoring in rebates and insurance discounts. The MFN pricing model is designed to disrupt this trend by eliminating the ability of drug companies to charge American consumers higher rates. Beyond cost savings, the White House also emphasized the strategic benefits of domestic pharmaceutical production, noting that the new Virginia facility will serve as a hub for producing advanced drug ingredients. President Trump described the agreement as a victory for American patients, promising that it would bring immediate relief to millions struggling with high medication costs and ensure they receive the best prices anywhere in the world.
